Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5938 Target Snapshot

Serine/threonine-protein kinase PLK2 · SINGLE PROTEIN · Homo sapiens

854Compounds
264Assays
4Approved Drugs
416.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt Q9NYY3. Use UniProt Q9NYY3 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9NYY3 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein kinase PLK2 as ChEMBL target CHEMBL5938, mapped to UniProt Q9NYY3. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serine/threonine-protein kinase PLK2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL5938
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9NYY3
Serine/threonine-protein kinase PLK2
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Serine/threonine-protein kinase PLK2 is the right protein anchor across sources, using UniProt Q9NYY3 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSerine/threonine-protein kinase PLK2
UniProt AccessionQ9NYY3
Component TypeProtein
Sequence Length685 aa

Serine/threonine-protein kinase PLK2

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Serine/threonine-protein kinase PLK2, mapped to UniProt Q9NYY3. Sequence length is 685 aa.

Mapped IDQ9NYY3
Review nameSerine/threonine-protein kinase PLK2
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

4
Approved
4
Phase III
5
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC50319.0
KI2.0
EC501.0
KD94.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL513909 9.09 Kd 0.81 Clinical
CHEMBL1094477 8.7 IC50 2.0 Preclinical
CHEMBL2205426 8.7 Ki 2.0 Preclinical
CHEMBL513909 8.54 IC50 2.92 Clinical
CHEMBL4166771 8.47 IC50 3.4 Preclinical
CHEMBL4592698 8.4 IC50 3.98 Preclinical
CHEMBL522618 8.4 IC50 4.0 Preclinical
CHEMBL4454222 8.33 IC50 4.72 Preclinical
CHEMBL4171770 8.31 IC50 4.88 Preclinical
CHEMBL1233528 8.3 IC50 5.0 Clinical
Distribution

pChEMBL Value Distribution

25
5.0
32
5.5
48
6.0
46
6.5
18
7.0
32
7.5
26
8.0
3
8.5
1
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

BOSUTINIB
CHEMBL288441
Approved 2012
Assay Landscape

Assay Landscape

264
Total Assays
219
Tested Compounds
3
Assay Types
Binding — 262 assays, 219 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 221 126 6.6
assay format 28 73 7.0
cell-based format 13 20 5.9
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 0
Functional — 1 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 1 8.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine